NeoGenomics, Inc.
NASDAQ:NEOMedical - Diagnostics & Research
+$0.63 today
- Market cap
- $1.99B
- Beta
- 1.81
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.84
Volume 1.09M
Average 1.94M
NEO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
NeoGenomics, Inc.NASDAQ: NEO
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $16.21M fell 6.1% year over year, ahead of the -8.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.
Context
- Depreciation & amortization amounted to 9.3% of revenue in FY2025, down 1.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -6.1% holds above the trailing-twelve-month pace of -8.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 67.82M USD
- Year-over-year change
- -6.5%
- 4-year CAGR
- +6.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.82M | -6.5% |
| FY2024 | 2024-12-31 | 72.55M | -0.0% |
| FY2023 | 2023-12-31 | 72.58M | +4.5% |
| FY2022 | 2022-12-31 | 69.43M | +30.1% |
| FY2021 | 2021-12-31 | 53.35M | — |
Depreciation & Amortization vs competitors
How NEO compares with its peers on the latest reported figures
- NEO's LTM Jun 2026 depreciation & amortization of $65.46M is the 2nd highest of the 10 companies compared; the peer median is $20.83M.
- Its year-over-year change of -8.0% is the 6th highest of 10, against a peer median of -2.3%.
- Depreciation & amortization amounts to 8.5% of revenue for NEO, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $155.37M | -1.1% | +0.3% | 94.0% | |
| LTM Jun 2026 | $65.46M | -8.0% | -0.8% | 8.5% | |
| LTM Mar 2026 | $51.8M | -13.5% | +0.6% | 6.2% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $26.88M | +15.1% | -24.8% | 5.9% |
| LTM Jun 2026 | $20.83M | -9.4% | -6.2% | 3.7% | |
| LTM Mar 2026 | $16.75M | -60.5% | +57.0% | 4.9% | |
| LTM Mar 2026 | $9.83M | -8.1% | +6.0% | 15.2% | |
| LTM Mar 2026 | $5.61M | +1.3% | -1.4% | 5.8% | |
| LTM Mar 2026 | $2.13M | +24.9% | +10.8% | 3.1% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding NEO) | $20.83M | -2.3% | +0.6% | 5.8% | |
Competitors are the stored peer set for NEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.33M | 509.73M | 591.64M | 660.57M | 727.33M |
| Cost of Revenue | 297.27M | 321.83M | 347.04M | 370.47M | 444.79M |
| Gross Profit | 187.06M | 187.9M | 244.6M | 290.1M | 282.54M |
| Gross Margin | 38.6% | 36.9% | 41.3% | 43.9% | 38.8% |
| Research & Development | 21.87M | 30.33M | 27.31M | 31.16M | 37.08M |
| Selling, General & Admin | 283.94M | 277.91M | 279.96M | 310.49M | 365.34M |
| Operating Expenses | 305.81M | 345.52M | 352.34M | 382.21M | 348.62M |
| Depreciation & Amortization | 53.35M | 69.43M | 72.58M | 72.55M | 67.82M |
| EBITDA | 46.5M | (82.33M) | (17.61M) | (1.51M) | (38.69M) |
| EBITDA Margin | 9.6% | -16.2% | -3.0% | -0.2% | -5.3% |
| Operating Income | (118.75M) | (157.62M) | (107.74M) | (92.11M) | (66.08M) |
| Operating Margin | -24.5% | -30.9% | -18.2% | -13.9% | -9.1% |
| Interest Income | 3.14M | 6.08M | 16.9M | 18.43M | 9.07M |
| Interest Expense | 8.22M | 7.58M | 6.91M | 6.62M | 3.75M |
| Other Income / Expenses | 103.68M | (1.72M) | 10.64M | 11.43M | (44.19M) |
| Income Before Tax | (15.08M) | (159.34M) | (97.1M) | (80.68M) | (110.27M) |
| Pre-Tax Margin | -3.1% | -31.3% | -16.4% | -12.2% | -15.2% |
| Income Tax Expense | (6.73M) | (15.09M) | (9.13M) | (1.95M) | (2.24M) |
| Net Income | (8.35M) | (144.25M) | (87.97M) | (78.73M) | (108.03M) |
| Net Margin | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% |
| EPS (Basic) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| EPS (Diluted) | (0.07) | (1.16) | (0.70) | (0.62) | (0.84) |
| Weighted Avg Shares | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
| Weighted Avg Shares (Diluted) | 119.96M | 124.22M | 125.5M | 126.66M | 128.1M |
NeoGenomics, Inc.
NASDAQ:NEO
Intrinsic Alpha fair value
Locked
Current Price
$15.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.